強直性脊椎炎の市場規模、シェア、成長分析：薬剤クラス別、流通チャネル別、地域別 - 産業予測 2025年～2032年

強直性脊椎炎の世界市場規模は2023年に67億8,000万米ドルと評価され、2024年の72億8,000万米ドルから2032年には128億9,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは7.4％で成長する見通しです。

慢性的な脊髄および関節の炎症を特徴とする世界の強直性脊椎炎市場は、世界の有病率と認知度の上昇に後押しされ、成長軌道に乗っています。診断方法の向上により早期発見が可能になり、治療成績の向上に寄与しています。医学研究の主な発展により、非ステロイド性抗炎症薬、TNF阻害剤、インターロイキン阻害剤などの革新的な治療法が導入され、患者のQOLが大幅に向上し、市場の需要が拡大しています。人口の高齢化、特に罹患頻度の高い男性の高齢化は、この成長をさらに後押ししています。しかし、曖昧な症状による過小診断、生物学的製剤による治療費の高騰、特定の地域における医療アクセスの制限といった課題に市場は直面しています。さらに、恒久的な治療法がないため、継続的な疾病管理が必要となり、市場の将来的なダイナミクスを形成しています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

強直性脊椎炎市場規模：薬剤クラス別& CAGR（2025-2032）

• 市場概要
• 非ステロイド性抗炎症薬（NSAID）
• TNF阻害剤
  • Humira
  • Simponi
  • Remicade
  • Enbrel
  • Cimzia
  • その他のTNF阻害剤
• その他の薬物クラス

強直性脊椎炎市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 病院薬局
• 小売薬局
• その他

強直性脊椎炎市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• AbbVie Inc.（United States）
• Amgen Inc.（United States）
• Pfizer Inc.（United States）
• Johnson & Johnson（United States）
• Novartis AG（Switzerland）
• UCB S.A.（Belgium）
• Eli Lilly and Company（United States）
• Merck & Co., Inc.（United States）
• Boehringer Ingelheim International GmbH（Germany）
• Gilead Sciences Inc.（United States）
• Bristol-Myers Squibb Company（United States）
• AstraZeneca plc（United Kingdom）
• Sanofi S.A.（France）
• GlaxoSmithKline plc（United Kingdom）
• Horizon Therapeutics plc（Ireland）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Sandoz International GmbH（Germany）
• Zydus Lifesciences Limited（India）
• Izana Bioscience（United Kingdom）

結論と推奨事項

Global Ankylosing Spondylitis Market size was valued at USD 6.78 billion in 2023 and is poised to grow from USD 7.28 billion in 2024 to USD 12.89 billion by 2032, growing at a CAGR of 7.4% during the forecast period (2025-2032).

The global ankylosing spondylitis market, characterized by chronic spinal and joint inflammation, is on a growth trajectory, propelled by rising global prevalence and awareness. Enhanced diagnostic methods enable early detection, contributing to improved treatment outcomes. Key developments in medical research have introduced innovative therapies, including NSAIDs, TNF inhibitors, and interleukin inhibitors, significantly enhancing patient quality of life and amplifying market demand. The aging population, particularly men who are more frequently affected, further fuels this growth. However, the market faces challenges such as underdiagnosis due to ambiguous symptoms, high costs of biologic therapies, and limited healthcare access in certain regions. Additionally, the absence of a permanent cure necessitates ongoing disease management, shaping the future dynamics of the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Ankylosing Spondylitis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Ankylosing Spondylitis Market Segments Analysis

Global Ankylosing Spondylitis Market is segmented by Drug Class, Distribution Channel and region. Based on Drug Class, the market is segmented into Non-Steroidal Anti Inflammatory Drug (NSAID), TNF Inhibitors and Other Drug Classes. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Ankylosing Spondylitis Market

Recent progress in medical research has enhanced our comprehension of ankylosing spondylitis, including its root causes and possible treatment options. The introduction of targeted therapies, particularly tumor necrosis factor (TNF) inhibitors and interleukin inhibitors, has notably transformed the management of this condition. The accessibility of effective medications, alongside the continuous refinement of treatment guidelines, plays a crucial role in driving the expansion of the global ankylosing spondylitis market. With ongoing advancements in therapeutic strategies and an increasing awareness of the disease, the market is poised for significant growth, addressing the unmet needs of individuals affected by this condition.

Restraints in the Global Ankylosing Spondylitis Market

The global ankylosing spondylitis market faces significant constraints due to the necessity of long-term disease management and ongoing treatment. Effective control of this condition hinges on patients' compliance with medication schedules, commitment to lifestyle changes, and regular medical follow-ups. These factors can pose challenges to consistent patient adherence and effective disease monitoring. As a result, the difficulties associated with sustained management of ankylosing spondylitis may hinder overall market growth, as patients struggle to maintain the necessary regimen for optimal health outcomes. Addressing these compliance issues is crucial for unlocking the potential of the ankylosing spondylitis treatment market.

Market Trends of the Global Ankylosing Spondylitis Market

The Global Ankylosing Spondylitis market is witnessing a significant trend towards early diagnosis and treatment, driven by the increasing recognition of the importance of timely intervention in managing this chronic inflammatory condition. Enhanced diagnostic techniques and heightened awareness among healthcare professionals and patients are contributing to an uptick in early detection rates. This proactive approach fosters prompt initiation of therapies aimed at controlling inflammation, alleviating symptoms, and staving off disease progression. Consequently, patient advocacy organizations and healthcare providers are intensifying educational campaigns, thereby shaping a market landscape that prioritizes optimal patient outcomes and drives demand for innovative treatment modalities.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Ankylosing Spondylitis Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Non-Steroidal Anti Inflammatory Drug(NSAID)
• TNF Inhibitors
  • Humira
  • Simponi
  • Remicade
  • Enbrel
  • Cimzia
  • Other TNF Inhibitors
• Other Drug Classes

Global Ankylosing Spondylitis Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Others

Global Ankylosing Spondylitis Market Size & CAGR (2025-2032)

• North America (Drug Class, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A. (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Horizon Therapeutics plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Izana Bioscience (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations